Pasireotide injection (Signifor®)

Signifor (pasireotide) injection is covered for adults (≥18) with Cushing's disease who are not surgical candidates or whose surgery was not curative, and as compendial use for adults with endogenous Cushing's syndrome awaiting surgery or awaiting therapeutic response after radiotherapy (pediatric use excluded); coverage requires prescription by or consultation with an endocrinologist/Cushing specialist, documentation of diagnosis and surgical/awaiting status, initial approval generally 4 months (reauthorization to 12 months only with documented clinical response), and dosing per label 0.3–0.9 mg SC twice daily with a lower start (0.3 mg BID, titrate to 0.6 mg BID) for Child‑Pugh B hepatic impairment.

"Signifor is indicated for the treatment of adult individuals with Cushing's disease for whom pituitary surgery is not an option or has not been curative."

Sign up to see full coverage criteria, indications, and limitations.